Search results

1. ESMO 2024 – Nuvalent looks beyond its late-line Alkove

   ESMO 2024 – Nuvalent looks beyond its late-line Alkove … ALK+ solid tumours   Triple meeting 2023 ESMO 2024 presentation Cutoff date 8 Aug 2023 … treated ROS1+ NSCLC   Triple Meeting 2022 ESMO 2024 presentation Cutoff date 13 Sep 2022 …

   
    

   Madeleine Armstrong
    
   - 09/15/2024 - 08:34

2. ESMO 2024 – MediLink impresses in small-cell lung cancer

   ESMO 2024 – MediLink impresses in small-cell lung cancer …

   
    

   Madeleine Armstrong
    
   - 09/14/2024 - 14:22

3. ESMO 2024 – NiKang’s case for a better Welireg

   ESMO 2024 – NiKang’s case for a better Welireg …

   
    

   Jacob Plieth
    
   - 09/14/2024 - 14:22

4. ESMO 2024 – degraders disappoint again

   ESMO 2024 – degraders disappoint again …

   
    

   Madeleine Armstrong
    
   - 09/14/2024 - 07:37

5. ESMO 2024 – no hiding Truqap’s triple-negative flop

   ESMO 2024 – no hiding Truqap’s triple-negative flop …

   
    

   Jacob Plieth
    
   - 09/14/2024 - 07:37

6. ESMO 2024 – Bristol heads for phase 3 in small-cell

   ESMO 2024 – Bristol heads for phase 3 in small-cell …

   
    

   Jacob Plieth
    
   - 09/16/2024 - 15:20

7. ESMO 2024 – changing FDA stance could haunt Astra’s Niagara win

   ESMO 2024 – changing FDA stance could haunt Astra’s …

   
    

   Jacob Plieth
    
   - 09/16/2024 - 11:00

8. ESMO 2024 preview – Summit could take on Merck in breast cancer

   ESMO 2024 preview – Summit could take on Merck in breast …

   
    

   Madeleine Armstrong
    
   - 09/13/2024 - 21:05

9. ESMO 2024 preview – Astellas’s KRAS degrader disappoints

   ESMO 2024 preview – Astellas’s KRAS degrader disappoints … degrader KRAS G12D inhibitor When presented ESMO 2024 ESMO 2023 Study Ph1 global study …

   
    

   Madeleine Armstrong
    
   - 10/04/2024 - 15:06

10. ESMO 2024 – how Merck overreached in endometrial

    ESMO 2024 – how Merck overreached in endometrial …

    
     

    Jacob Plieth
     
    - 09/14/2024 - 07:37